MedTech Terms
    The authoritative reference
    All terms

    Total Product Lifecycle

    FDA framework integrating premarket and post-market oversight across a device's life.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    TPLC treats premarket review, post-market surveillance, manufacturing controls, and software updates as a connected continuum rather than discrete events. The TPLC database links 510(k), PMA, recall, MDR, and inspection data per device type.
    What the regulation says
    The FDA emphasizes TPLC in its guidance for Artificial Intelligence/Machine Learning (AI/ML)-enabled medical devices, viewing it as crucial for ensuring safety and effectiveness throughout the device's entire existence. This approach integrates premarket and postmarket activities, recognizing that device performance may evolve, particularly with adaptive AI/ML algorithms. The FDA’s "Guidance for Content of Premarket Submissions for Device Software Functions" further underlines the importance of managing device software throughout its lifecycle, including updates and modifications.

    What this means in practice

    Especially central to AI/ML devices, where post-market performance monitoring and PCCP-driven updates are part of the regulatory lifecycle.

    Examples

    • An AI-powered diagnostic tool for radiology continually monitors its performance in clinical use, and when new data indicates a potential bias, the manufacturer uses the TPLC framework to update the algorithm and resubmit for regulatory review.
    • A continuous glucose monitor with an AI algorithm receives a software update to improve accuracy, and the manufacturer, following TPLC principles, documents the validation, risk assessment, and regulatory submission for the change.
    • After several years on the market, a surgical robot's software is completely re-architected to incorporate new features, necessitating a comprehensive TPLC review of the design, verification, and validation, similar to an initial market submission.
    Common pitfalls
    • •A common pitfall is treating premarket approval as the end of regulatory oversight, rather than an ongoing process, especially for rapidly evolving technologies like AI/ML. Another mistake is failing to integrate post-market surveillance data effectively into product development and risk management processes. Companies often underestimate the resources required for continuous monitoring and updates throughout the product's entire lifecycle.
    • •Overlooking the need for a robust change management process for software updates can lead to regulatory non-compliance.
    • •Failing to maintain traceability between software versions, risk assessments, and clinical performance data is a significant pitfall.

    Frequently asked questions

    AI/ML devices can adapt and learn from real-world data, meaning their performance may change after initial market authorization. TPLC provides a framework for continuously monitoring and managing these changes, ensuring ongoing safety and effectiveness.

    Cross-references

    See also

    Closely related context worth reading.

    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    FDA·2MDCG·1
    1. 1
      TPLC Database
      Verified
      FDAaccessdata.fda.gov
    2. 2
      MDCG Software Guidance
      Verified
      MDCGhealth.ec.europa.eu
    3. 3
      FDA - Software as a Medical Device (SaMD)
      Verified
      FDAfda.gov

    Inline markers like [1] jump to the matching reference above.